Literature DB >> 8003056

Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity.

P Seideman1, F Albertioni, O Beck, S Eksborg, C Peterson.   

Abstract

OBJECTIVE: To evaluate the effects of a single dose of chloroquine (CQ) on the pharmacokinetics of methotrexate (MTX) in patients with rheumatoid arthritis.
METHODS: Eleven patients (ages 41-75 years) who were taking oral doses of MTX (15 mg/week) were studied after a dose of MTX alone and after a dose of MTX plus CQ (250 mg). Plasma and urine samples were collected for 24 hours after dose intake, and the concentrations of MTX and its major metabolite 7-hydroxymethotrexate were determined by high-performance liquid chromatography.
RESULTS: Administration of CQ together with MTX caused a reduction in the area under the plasma MTX concentration versus time curve (AUC). The median value of individual AUC ratios (MTX/MTX + CQ) was 1.6 (95% confidence interval 1.2-3.6).
CONCLUSION: The most likely mechanism for the interaction is that CQ reduces the bioavailability of MTX. This gives a possible explanation for a suggested reduction in MTX-associated liver toxicity by coadministration of CQ. The significance of the interaction for the therapeutic effect remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8003056     DOI: 10.1002/art.1780370609

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

Review 1.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

2.  Use of methotrexate in older patients. A risk-benefit assessment.

Authors:  S E Tett; E J Triggs
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

Review 3.  Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.

Authors:  Mariana Babayeva; Zvi Loewy
Journal:  Pharmgenomics Pers Med       Date:  2020-10-23

4.  Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics.

Authors:  F Albertioni; B Flatø; P Seideman; O Beck; O Vinje; C Peterson; S Eksborg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Synergistic Effects of BTK Inhibitor HM71224 and Methotrexate in a Collagen-induced Arthritis Rat Model.

Authors:  Kyung Jin Choi; Yu-Yon Kim; Sun Young Jang; Young Gil Ahn; Kwee Hyun Suh; Young Hoon Kim; Hyung Sik Kim
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 6.  Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy.

Authors:  R Matthew Chico; Daniel Chandramohan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-07-07       Impact factor: 4.481

Review 7.  Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.

Authors:  Haleh Rezaee; Fariba Pourkarim; Samira Pourtaghi-Anvarian; Taher Entezari-Maleki; Touraj Asvadi-Kermani; Masoud Nouri-Vaskeh
Journal:  Pharmacol Res Perspect       Date:  2021-02

Review 8.  Clinically important drug interactions with disease-modifying antirheumatic drugs.

Authors:  C J Haagsma
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 4.271

Review 9.  Repurposing New Use for Old Drug Chloroquine against Metabolic Syndrome: A Review on Animal and Human Evidence.

Authors:  Sok Kuan Wong
Journal:  Int J Med Sci       Date:  2021-05-13       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.